---
title: "Carisma Therapeutics 於 6 月 26 日通知諾華製藥終止公司與諾華製藥之間的製造和供應協議"
description: "Carisma Therapeutics 已於 2024 年 7 月 31 日終止了與諾華製藥的製造和供應協議。該公司現在將專注於其後續產品候選藥物 CT-0525，用於體外腫瘤臨牀開發。其針對 CT-0508 的一期臨牀試驗的新患者招募已暫停"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/207818143.md"
published_at: "2024-07-02T21:01:51.000Z"
---

# Carisma Therapeutics 於 6 月 26 日通知諾華製藥終止公司與諾華製藥之間的製造和供應協議

> Carisma Therapeutics 已於 2024 年 7 月 31 日終止了與諾華製藥的製造和供應協議。該公司現在將專注於其後續產品候選藥物 CT-0525，用於體外腫瘤臨牀開發。其針對 CT-0508 的一期臨牀試驗的新患者招募已暫停

7 月 2 日 (路透社) - Carisma Therapeutics Inc (CARM.O) :

## CARISMA THERAPEUTICS：於 6 月 26 日通知諾華製藥終止公司與諾華製藥之間的製造和供應協議

## CARISMA THERAPEUTICS INC - 公司與諾華製藥之間的製造和供應協議終止，自 2024 年 7 月 31 日起生效

## CARISMA THERAPEUTICS - 公司決定將外體腫瘤臨牀開發工作集中在其後續產品候選 CT-0525 上

CARISMA THERAPEUTICS INC - 已暫停其 CT-0508 一期臨牀試驗的新患者招募

### Related Stocks

- [CARM.US - Carisma Therapeutics](https://longbridge.com/zh-HK/quote/CARM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Carisma Therapeutics Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down | Carisma Therapeutics Inc. has announced separation agreements for its CEO Steven Kelly and CSO Michael Klichinsky as the | [Link](https://longbridge.com/zh-HK/news/261316519.md) |
| Carisma Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview | Carisma Therapeutics Inc is anticipated to report a loss of 12 cents per share for the quarter ending September 30, 2025 | [Link](https://longbridge.com/zh-HK/news/264052760.md) |
| Carisma Therapeutics Amends Agreement with Moderna, Receives $4 Million Payment | Carisma Therapeutics Inc. has amended its Collaboration and License Agreement with ModernaTX, Inc., effective September  | [Link](https://longbridge.com/zh-HK/news/257933444.md) |
| Carisma Therapeutics Delists Common Stock | Carisma Therapeutics Inc. has filed to deregister its common stock, terminating its reporting obligations as a public co | [Link](https://longbridge.com/zh-HK/news/270996498.md) |
| Ocugen Inc. Announces Termination of Merger Agreement with Carisma Therapeutics Due to Funding Shortfall | Ocugen Inc. has terminated its merger agreement with Carisma Therapeutics due to a funding shortfall. The merger, initia | [Link](https://longbridge.com/zh-HK/news/257950392.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
